GlassScriptPhysician profile
Thomas M Sisk
NPI 1710985932
$7,148.12
in general payments reported to CMS, 2019-2025
22 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $648 · 2021: $1,044 · 2022: $1,278 · 2023: $1,431 · 2024: $1,463 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,172 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,171.97 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,462.12 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,223.76 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,215.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $898.78 | 2020-2025 | Farxiga, Airsupra |
| Pfizer INC. | $837.87 | 2020-2025 | |
| Philips North America LLC | $446.43 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Abbvie INC. | $278.71 | 2023-2025 | Qulipta, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $179.07 | 2023-2025 | |
| Exact Sciences Corporation | $136.62 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $90.82 | 2023-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $80.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.33 | 2022-2023 | Stiolto Respimat |
| Amgen INC. | $51.31 | 2022-2023 | Repatha, Otezla |
| Pulmonx Corporation | $28.79 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Ultragenyx Pharmaceutical INC. | $28.61 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24.56 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.54 | 2021 | |
| Abbott Laboratories | $18.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.20 | 2022 | |
| Currax Pharmaceuticals LLC | $17.14 | 2022 | |
| Dexcom, INC. | $16.39 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $16.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sisk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.